Jon Arnason

8.3k total citations · 2 hit papers
120 papers, 3.2k citations indexed

About

Jon Arnason is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Jon Arnason has authored 120 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 48 papers in Immunology and 40 papers in Genetics. Recurrent topics in Jon Arnason's work include CAR-T cell therapy research (53 papers), Chronic Lymphocytic Leukemia Research (39 papers) and Lymphoma Diagnosis and Treatment (34 papers). Jon Arnason is often cited by papers focused on CAR-T cell therapy research (53 papers), Chronic Lymphocytic Leukemia Research (39 papers) and Lymphoma Diagnosis and Treatment (34 papers). Jon Arnason collaborates with scholars based in United States, Germany and Israel. Jon Arnason's co-authors include Tim Sparwasser, Hermann Wagner, Christoph Loddenkemper, Jeremy S. Abramson, Jennifer Freyer, Gérard Eberl, Jochen Huehn, Katharina Lahl, Alf Hamann and Jennifer R. Brown and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jon Arnason

112 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease

2007 722 citations Katharina Lahl, Christoph Loddenkemper et al. The Journal of Experimental Medicine profile →
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jon Arnason United States	27	1.6k	1.4k	988	756	615	120	3.2k
Javier Briones Spain	35	1.9k 1.2×	1.7k 1.2×	1.3k 1.4×	957 1.3×	831 1.4×	161	4.5k
Mikhail Roshal United States	27	2.3k 1.5×	862 0.6×	532 0.5×	439 0.6×	1.4k 2.3×	103	4.3k
Daniel J. Landsburg United States	23	2.4k 1.5×	721 0.5×	908 0.9×	408 0.5×	722 1.2×	136	3.3k
Sarah Nikiforow United States	31	1.8k 1.1×	1.4k 1.0×	282 0.3×	354 0.5×	463 0.8×	152	3.4k
Anita Schmitt Germany	33	1.7k 1.1×	1.6k 1.2×	176 0.2×	418 0.6×	1.0k 1.7×	142	3.5k
Kevin A. Hay Canada	19	3.2k 2.0×	770 0.6×	460 0.5×	419 0.6×	761 1.2×	42	3.9k
Dirk Nagorsen United States	33	2.7k 1.7×	2.3k 1.7×	682 0.7×	285 0.4×	961 1.6×	88	4.4k
Justin Kline United States	33	2.8k 1.8×	3.6k 2.6×	576 0.6×	383 0.5×	1.2k 1.9×	146	5.5k
Maher K. Gandhi Australia	35	2.5k 1.5×	1.7k 1.3×	1.5k 1.5×	347 0.5×	690 1.1×	133	4.5k
Constance M. Yuan United States	31	4.2k 2.7×	1.7k 1.2×	1.2k 1.2×	1.2k 1.6×	1.5k 2.4×	121	5.9k

Countries citing papers authored by Jon Arnason

Since Specialization

Citations

This map shows the geographic impact of Jon Arnason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Arnason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Arnason more than expected).

Fields of papers citing papers by Jon Arnason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Arnason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Arnason. The network helps show where Jon Arnason may publish in the future.

Co-authorship network of co-authors of Jon Arnason

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Arnason. A scholar is included among the top collaborators of Jon Arnason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Arnason. Jon Arnason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arnason, Jon, Matthew J. Matasar, Stefano Luminari, et al.. (2025). Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Advances. 9(23). 6130–6140.

Bindal, Poorva, Caitlin A. Trottier, Laura E. Dodge, et al.. (2024). Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy. Leukemia & lymphoma. 66(4). 702–712. 3 indexed citations

Arnason, Jon, et al.. (2024). CARs for lymphoma. Best Practice & Research Clinical Haematology. 37(4). 101601–101601.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465. 1 indexed citations

Kamdar, Manali, Scott R. Solomon, Jon Arnason, et al.. (2024). Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.. Journal of Clinical Oncology. 42(16_suppl). 7013–7013. 6 indexed citations

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.

Ahrendsen, Jared T., Kartik Sehgal, Sasmit Sarangi, et al.. (2021). Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma. Journal of Hematology. 10(5). 212–216. 5 indexed citations

Tyekucheva, Svitlana, Zixu Wang, Alexander R. Vartanov, et al.. (2021). A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 36(3). 723–732. 14 indexed citations

Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2019). Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood. 134(Supplement_1). 241–241. 89 indexed citations

10.

Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2018). Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study. The Lancet Haematology. 6(1). e38–e47. 90 indexed citations

11.

Jain, Salvia, Abigail Washington, Rebecca Karp Leaf, et al.. (2017). Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Molecular Cancer Therapeutics. 16(10). 2304–2314. 10 indexed citations

12.

Maloney, David G., Jeremy S. Abramson, Maria Lia Palomba, et al.. (2017). Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration. Blood. 130. 1552–1552. 9 indexed citations

13.

Lampson, Benjamin L., Haesook T. Kim, Matthew S. Davids, et al.. (2017). Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia. Blood. 130. 1734–1734. 4 indexed citations

14.

Siddiqi, Tanya, Jeremy S. Abramson, D. Li, et al.. (2017). Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017. Blood. 130. 193–193. 14 indexed citations

15.

Arnason, Jon & Jennifer R. Brown. (2017). Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Current Oncology Reports. 19(9). 61–61. 14 indexed citations

16.

Lampson, Benjamin L., Siddha Kasar, Tiago R. Matos, et al.. (2016). Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 128(2). 195–203. 227 indexed citations

17.

Jain, Salvia, Dina Stroopinsky, Yin Li, et al.. (2015). Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 126(3). 354–362. 28 indexed citations

18.

Stroopinsky, Dina, Jacalyn Rosenblatt, Keisuke Ito, et al.. (2013). MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. Cancer Research. 73(17). 5569–5579. 41 indexed citations

19.

Levy, Benjamin, Jon Arnason, & James B. Bussel. (2008). The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. Current Opinion in Oncology. 20(6). 690–696. 14 indexed citations

20.

Lahl, Katharina, Christoph Loddenkemper, Jennifer Freyer, et al.. (2007). Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. The Journal of Experimental Medicine. 204(1). 57–63. 722 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact